Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls.
Hilary S Whitworth, Khalid B Beshir, Kathy J Baisley et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the impact of malaria parasitaemia on HPV vaccine immune responses in 930 HIV-negative Tanzanian schoolgirls aged 9-14 years. The study found that in the two-dose Cervarix® and Gardasil®9 arms, participants with malaria had lower HPV16 and HPV18 antibody geometric mean concentrations (GMCs) and avidity indices (AIs) at month 36, with ratios of 0.74 and 0.58, respectively. No differences were observed in the one-dose arms.
Key findings
- In the two-dose Cervarix® arm, HPV16 GMCs were lower in participants with malaria (GMC ratio = 0.74).
- In the two-dose Gardasil®9 arm, HPV18 GMCs were lower in participants with malaria (GMC ratio = 0.58).
- No differences in antibody responses were found in the one-dose arms between those with and without malaria.
Why it matters
Understanding the effects of malaria on HPV vaccine responses is crucial for optimizing vaccination strategies in regions where malaria is endemic. This study provides insights into potential immunological interactions that could influence vaccine efficacy.